Table 5. Univariate and multivariate analyses of prognostic factors for locoregional recurrence-free survival.

			Univariate analysis		Multivariate analysis
	N	10-year LRRFS (%) (IC 95%)	P a	RR (IC 95%)	P b	RR (IC 95%)
Age (continuous variable)			0.015	0.97 (0.96–1.00)
Age (dummy variable) c			<10−6		<10−3
>40	597	79 (75–82)		1		1
⩽40	153	60 (51–70)		2.2 (1.6–3.1)		2.3 (1.6–3.2)
Menopause			0.5
No	563	73 (69–78)		1
Yes	187	79 (73–86)		0.9 (0.6–1.3)
Clinical tumour stage c			0.35
cT2	556	74 (69–78)		1
cT3	194	78 (72–86)		0.8 (0.6–1.2)
Clinical nodal status c			0.33
cN0	465	76 (71–80)		1
cN1	285	74 (68–80)		1.2 (0.8–1.6)
Histological type			0.9
Ductal	672	75 (71–79)		1
Lobular	78	73 (62–86)		1 (0.6–1.7)
Hormonal receptors c			0.05		0.02
HR+	466	75 (71–80)		1		1
HR−	166	69 (62–78)		1.4 (1.0–2.0)		1.7 (1.2–2.5)
Histological grade			0.34
Grade 1	114	82 (75–90)		1
Grade 2	362	73 (68–79)		1.3 (0.8–2.0)
Grade 3	217	73 (67–81)		1.4 (0.9–2.4)
Mitotic index			0.48
Grade 1	182	79 (72–87)		1
Grade 2	189	77 (70–84)		1.2 (0.7–1.9)
Grade 3	297	75 (69–81)		1.3 (0.8–2.0)
Clinical response			0.72
⩾50%	434	78 (74–83)		1
<50%	309	76 (70–82)		1.1 (0.8–1.5)

HR=hormonal receptor; LRRFS=locoregional recurrence-free survival

^aLog-rank test.

^bLikelihood ratio test.

^cFactors entered in the multivariate analysis.